Tramadol extended-release formulations in the management of pain due to osteoarthritis

Expert Review of Neurotherapeutics

Volumn 7, Issue 12, 2007, Pages 1775-1784

  Mongin, Gérald ^a  

^a General Practice   (France)

Author keywords

Analgesia; Controlled release; Once daily formulation; Pain; Tramadol

Indexed keywords

TRAMADOL;

CONSTIPATION; DIZZINESS; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; DRUG EFFICACY; DRUG FORMULARY; DRUG HALF LIFE; DRUG RELEASE; DRUG SAFETY; DRUG TOLERABILITY; HUMAN; INCIDENCE; NAUSEA; OSTEOARTHRITIS; PAIN; REVIEW; SOMNOLENCE;

ANALGESICS, OPIOID; CLINICAL TRIALS AS TOPIC; DELAYED-ACTION PREPARATIONS; HUMANS; OSTEOARTHRITIS; PAIN; TRAMADOL;

EID: 37149028732     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.12.1775     Document Type: Review

References (42)

1. Goodwin JL, Kraemer JJ, Bajwa ZH. The use of opioids in the treatment of osteoarthritis: when, why, and how? Curr. Pain Headache Rep. 9(6), 390-398 (2005).
2. Schnitzer TJ. Update on guidelines for the treatment of chronic musculoskeletal pain. Clin. Rheumatol. 25(Suppl. 1), 22-29 (2006).
3. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Recommendations for the Medical Management of Osteoarthritis of the Hip and Knee: 2000 Update. Arthritis Rheum. 43(9), 1905-1915 (2000).
4. Jordan KM, Arden NK, Doherty M et al. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a task force of the standing committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann. Rheum. Dis. 62(12), 1145-1155 (2003).
5. American Pain Society guideline for treatment of arthritis pain. J. Pain Palliat. Care Pharmacother. 16(4), 130-132 (2002).
6. Hair PI, Curran MP, Keam SJ. Tramadol extended-release tablets. Drugs 66(15), 2017-2027; discussion 2028-2030 (2006).
7. Adler L, McDonald C, O'Brien C, Wilson M. A comparison of once-daily tramadol with normal release tramadol in the treatment of pain in osteoarthritis. J. Rheumatol. 29(10), 2196-2199 (2002). •• Presents results of a double-blind active-controlled (immediate-release) study of the Mundipharma once-daily formulation.
8. Babul N, Noveck R, Chipman H et al. Efficacy and safety of extended-release, once-daily tramadol in chronic pain: a randomized 12-week clinical trial in osteoarthritis of the knee. J. Pain Symptom Manage. 28(1), 59-71 (2004). •• Presents results of a double-blind placebo-controlled study of the Biovail once-daily formulation.
9. Burch F, Fishman R, Messina N et al. A comparison of the analgesic efficacy of tramadol contramid OAD vs placebo in patients with pain due to osteoarthritis. J. Pain Symptom Manage. 34(3), 328-338 (2007). •• Presents results of a double-blind placebo-controlled study of the Labopharm Inc. once-daily formulation.
10. Keating GM. Tramadol sustained-release capsules. Drugs 66(2), 223-230 (2006).
11. Malonne H, Coffiner M, Fontaine D et al. Long-term tolerability of tramadol LP, a new once-daily formulation, in patients with osteoarthritis or low back pain. J. Clin. Pharm. Ther. 30(2), 113-120 (2005). •• Presents safety results regarding the SMB formulation.
12. Malonne H, Coffiner M, Sonet B, Sereno A, Vanderbist F. Efficacy and tolerability of sustained-release tramadol in the treatment of symptomatic osteoarthritis of the hip or knee: a multicenter, randomized, double-blind, placebo-controlled study. Clin. Ther. 26(11), 1774-1782 (2004). •• Presents results of a double-blind placebo-controlled study of the SMB once-daily formulation.
13. Hernandez-Lopez C, Martinez-Farnos L, Karhu D et al. Comparative bioavailability between two tramadol once-daily oral formulations. Methods Find. Exp. Clin. Pharmacol. 28(6), 373-378 (2006). •• Presents a head-to-head comparison of the pharmacokinetics of the Labopharm Inc. formulation versus the Mundipharma (Zambon) formulation.
14. Lee CR, McTavish D, Sorkin EM. Tramadol. A preliminary review of its pharmacodynamic and pharmacokinetic properties, and therapeutic potential in acute and chronic pain states. Drugs 46(2), 313-340 (1993).
15. Grond S, Sablotzki A. Clinical pharmacology of tramadol. Clin. Pharmacokinet. 43(13), 879-923 (2004).
16. Claxton AJ, Cramer J, Pierce C. A systematic review of the associations between dose regimens and medication compliance. Clin. Ther. 23(8), 1296-1310 (2001).
17. Bodalia B, McDonald CJ, Smith KJ, O'Brien C, Cousens L. A comparison of the pharmacokinetics, clinical efficacy, and tolerability of once-daily tramadol tablets with normal release tramadol capsules. J. Pain Symptom Manage. 25(2), 142-149 (2003). • Presents results of a pharmacokinetics study, as well as the clinical safety and efficacy of the Mundipharm once-daily formulation.
18. Mongin G, Yakusevich V, Köpe A et al. Efficacy and safety assessment of a novel once-daily tablet formulation of tramadol: a randomised, controlled study versus twice-daily tramadol in patients with osteoarthritis of the knee. Clin. Drug Invest. 24(9), 545-558 (2004). •• Presents results of a double-blind active-controlled (twice-daily formulation) study of the Labopharm Inc. once-daily formulation.
19. Gana TJ, Pascual ML, Fleming RR et al. Extended-release tramadol in the treatment of osteoarthritis: a multicenter, randomized, double-blind, placebo-controlled clinical trial. Curr. Med. Res. Opin. 22(7), 1391-1401 (2006). •• Presents results of the placebo-controlled efficacy study of the Biovail formulation in osteoarthritis.
20. Fishman RL, Kistler CJ, Ellerbusch MT et al. Efficacy and safety of 12 weeks of osteoarthritic pain therapy with once-daily tramadol (Tramadol Contramid® OAD). J. Opioid Management (2007) (In Press). •• Presents results of the placebo-controlled efficacy study of the Labopharm Inc. formulation.
21. Mattia C, Coluzzi F. Once-daily tramadol in rheumatological pain. Expert Opin. Pharmacother. 7(13), 1811-1823 (2006).
22. Malonne H, Sonet B, Streel B et al. Pharmacokinetic evaluation of a new oral sustained release dosage form of tramadol. Br. J. Clin. Pharmacol. 57(3), 270-278 (2003). • Presents the pharmacokinetics of the SMB formulation.
23. Karhu D, Bouchard S. Pharmacokinetic evaluation of a novel once-a-day tramadol hydrochloride formulation. Presented at: American College of Clinical Pharmacology (ACCP) Annual Meeting. Rockville, USA, 11-13 September 2005 (Poster 14). • Presents the pharmacokinetics of the Labopharm Inc. formulation.
24. Tiwari SB, Murthy TK, Pai MR, Mehta PR, Chowdary PB. Controlled release formulation of tramadol hydrochloride using hydrophilic and hydrophobic matrix system. AAPS PharmSciTech. 4(3), E31 (2003).
25. Hair PI, Curran MP, Keam SJ. Tramadol extended-release tablets in moderate to moderately severe chronic pain in adults: profile report. CNS Drugs 21(3), 259-263 (2007).
26. SRL Ultram® Extended-Release Tablets, prescribing information. Biovail Laboratories International, ON, Canada (2005).
27. Lenaerts V, Moussa I, Dumoulin Y et al. Cross-linked high amylose starch for controlled release of drugs: recent advances. J. Control. Release 53(1-3), 225-234 (1998).
28. Hancock BC, Carlson GT, Ladipo DD, Langdon BA, Mullarney MP. The powder flow and compact mechanical properties of two recently developed matrix-forming polymers. J. Pharm. Pharmacol. 53(9), 1193-1199 (2001).
29. Radulescu F, Sarbu A, Stroescu S et al. Long-term safety, tramadol contramid® OAD in pain treatment. Presented at: The 17th Annual clinical meeting of the American Academy of Pain Management. Orlando, FL, USA, 7 September 2006. • Presents the long-term safety (International Conference on Harmonisation criteria) of the Labopharm Inc. formulation.
30. Karhu D, Bouchard S. Comparative bioavailability of tramadol contramid® once-a-day and tramadol immediate-release tablets. Presented at: The American Academy of Pain Medicine, 23rd Annual Meeting. New Orleans, LA, USA, 7-10 February 2007 (Poster 145). • Presents the pharmacokinetics of the Labopharm Inc. formulation.
31. International Conference on Harmonisation of the Technical Requirements for Registration of Pharmaceuticals for Human Use (ICH) Guideline for Industry: the extent of population exposure to assess clinical safety: for drugs intended for long term treatment of non-life-threatening conditions.
32. Burch F, Fishman R, Hunt T et al. Safety data for tramadol Contramid® OAD in treatment of pain. Presented at: The 17th Annual clinical meeting of the American Academy of Pain Management. Orlando, FL, USA, 7-9 September 2006. • Presents results of a double-blind placebo-controlled study of the Labopharm Inc. once-daily formulation.
33. Mattia C, Coluzzi F. COX-2 inhibitors: pharmacological data and adverse effects. Minerva Anestesiol. 71(7-8), 461-470 (2005).
34. Katz WA, Rothenberg R. Section 4: treating the patient in pain. J. Clin. Rheumatol. 11(Suppl. 2), S16-S27, discussion S27-S28 (2005).
35. Lai JC, Sista S, Eradiri O. The pharmacokinetics of novel once daily tramadol hydrochloride extended release tablets in healthy subjects. Presented at: Annual Meeting of the American Association of Pharmaceutical Scientists. Salt Lake City, UT, USA, 26-30 October 2003 (Abstract M1071).
36. Bond MJ, Breivik H: Why pain control matters in a world full of killer diseases. Pain: Clinical Updates 12(4), 1-4 (2004).
37. Gibson S. Older people's pain. Pain: Clinical updates 14(3), 1-4 (2006).
38. Helme RD Gibson SJ. The epidemiology of pain in elderly people. Clin. Geriatr. Med. 17(3), 417-431 (2001).
39. Biovail Corporation www.biovail.com
40. VIDAL Médicaments Topalgic® LP tramadol (2007) www.vidalpro.net/monographies/fiches/VF900054.htm
41. Mundipharma International Limited www.mundipharma.co.uk
42. Labopharm Inc. www.labopharm.com